中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | syn (1R,2S)-N-benzyloxycarbonyl-N-(3,3,3-trifluoro-2-hydroxy-1-(isopropyl)-propyl) L-valinamide | —— | C19H27F3N2O4 | 404.43 |
设计了新的氟化抑制剂,以针对两种主要的蛋白酶——人白细胞弹性蛋白酶和HIV-1蛋白酶。
设计了两系列β-肽三氟甲基醇(TFMA)Z-L-Val-NH-*CH(Y)-*CH(OH)-CF3,其中*C为手性中心,取决于取代基Y的芳基乙基[-(CH2)2-C6H5]或异丙基[-CH(CH3)2]。这些TFMA首先作为两对syn和anti对映异构体合成。然后在基于取代基的芳香和脂肪性质的基础上,对这些混合物在三种丝氨酸蛋白酶——人白细胞弹性蛋白酶(HLE)、人猫蛋白酶G(HCG)和猪胰蛋白酶(PPE)上的抑制作用进行评估。在检测到抑制作用的情况下,分离每个C2上的对映异构体以确定其对HLE、HCG和PPE的抑制常数(Ki)。然后将立体异构纯TFMA氧化成肽三氟甲基酮=5·65×10−4 M)。测试的化合物还具有与HIV-1蛋白酶识别兼容的结构特性。只有TFMK才观察到酶的抑制作用(IC50 = 15-200 μM)。与异丙基取代基(IC50 = 200 μM)相比,芳基乙基取代基促进了10倍的抑制(IC50 = 15μM),导致对HIV-1蛋白酶的选择性抑制。
立体异构纯TFMK比它们所得到的醇更有效地针对HLE。然而,对映异构体纯TFMA选择性地抑制HLE,而其TFMK类似物也抑制PPE。这个结果以及TFMK具有芳基乙基取代基的选择性抑制HIV-1蛋白酶,可能与设计特定的HLE和HIV-1抑制剂作为治疗剂有关。
New fluorinated inhibitors have been designed to target two major proteases—human leucocyte elastase and HIV-1 protease.
Two series of β-peptidyl trifluoromethyl alcohols (TFMAs) Z-L-Val-NH-*CH(Y)-*CH(OH)-CF3, where *C is the chiral centre, varied in the nature of the substituent Y, a phenylethyl [-(CH2)2-C6H5] or an isopropyl [-CH(CH3)2] group. These TFMAs were first synthesized as two pairs of the syn and anti diastereoisomers. The inhibitory effects of these mixtures were then assessed on three serine proteases chosen on the basis of the aromatic and aliphatic nature of the substituents—human leucocyte elastase (HLE), human cathepsin G (HCG) and porcine pancreatic elastase (PPE). In the presence of detectable inhibition, each epimer at C2 was separated to determine its inhibition constant (Ki) towards HLE, HCG and PPE. The stereoisomerically pure TFMAs were then oxidized into peptidyl trifluoromethyl ketones = 5·65 × 10−4 M). The tested compounds also had structural properties compatible with recognition by HIV-1 protease. The inhibition of the enzyme was observed with TFMK only (IC50 = 15–200 μM). The phenylethyl substituent promoted inhibition by a factor of 10 (IC50 = 15μM) compared with the isopropyl substituent (IC50 = 200 μM) leading to selective inhibition of HIV-1 protease.
Isomerically pure TFMKs were more potent towards HLE than the alcohols from which they were obtained. However, an enantiomerically pure TFMA selectively inhibited HLE unlike its TFMK analogue which also inhibited PPE. This last result together with the selective inhibition of HIV-1 protease by TFMK with a phenylethyl substituent might be relevant to the design of specific HLE and HIV-1 inhibitors as therapeutic agents.
设计了新的氟化抑制剂,以针对两种主要的蛋白酶——人白细胞弹性蛋白酶和HIV-1蛋白酶。
设计了两系列β-肽三氟甲基醇(TFMA)Z-L-Val-NH-*CH(Y)-*CH(OH)-CF3,其中*C为手性中心,取决于取代基Y的芳基乙基[-(CH2)2-C6H5]或异丙基[-CH(CH3)2]。这些TFMA首先作为两对syn和anti对映异构体合成。然后在基于取代基的芳香和脂肪性质的基础上,对这些混合物在三种丝氨酸蛋白酶——人白细胞弹性蛋白酶(HLE)、人猫蛋白酶G(HCG)和猪胰蛋白酶(PPE)上的抑制作用进行评估。在检测到抑制作用的情况下,分离每个C2上的对映异构体以确定其对HLE、HCG和PPE的抑制常数(Ki)。然后将立体异构纯TFMA氧化成肽三氟甲基酮=5·65×10−4 M)。测试的化合物还具有与HIV-1蛋白酶识别兼容的结构特性。只有TFMK才观察到酶的抑制作用(IC50 = 15-200 μM)。与异丙基取代基(IC50 = 200 μM)相比,芳基乙基取代基促进了10倍的抑制(IC50 = 15μM),导致对HIV-1蛋白酶的选择性抑制。
立体异构纯TFMK比它们所得到的醇更有效地针对HLE。然而,对映异构体纯TFMA选择性地抑制HLE,而其TFMK类似物也抑制PPE。这个结果以及TFMK具有芳基乙基取代基的选择性抑制HIV-1蛋白酶,可能与设计特定的HLE和HIV-1抑制剂作为治疗剂有关。